{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T03:03:57Z","timestamp":1779851037465,"version":"3.53.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-026-04022-5","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:27:09Z","timestamp":1776414429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding kratom: molecular mechanisms and epigenetic factors in use and dependence"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6370-8731","authenticated-orcid":false,"given":"Edyham","family":"Misnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1295-7382","authenticated-orcid":false,"given":"Nur Zahidah Aqilah","family":"Hasbullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusdi","family":"Abd Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3155-4661","authenticated-orcid":false,"given":"Aishah","family":"Mohd Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7848-0775","authenticated-orcid":false,"given":"Maw Shin","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"4022_CR1","doi-asserted-by":"publisher","first-page":"e2805","DOI":"10.1002\/hup.2805","volume":"37","author":"E Prevete","year":"2022","unstructured":"Prevete E, Kuypers KPC, Theunissen EL, Corazza O, Bersani G, Ramaekers JG. A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans. Hum Psychopharmacol. 2022;37:e2805. https:\/\/doi.org\/10.1002\/hup.2805.","journal-title":"Hum Psychopharmacol"},{"key":"4022_CR2","doi-asserted-by":"publisher","first-page":"1403140","DOI":"10.3389\/fphar.2024.1403140","volume":"15","author":"JE Henningfield","year":"2024","unstructured":"Henningfield JE, Grundmann O, Huestis MA, Smith KE. Kratom safety and toxicology in the public health context: research needs to better inform regulation. Front Pharmacol. 2024;15:1403140. https:\/\/doi.org\/10.3389\/fphar.2024.1403140.","journal-title":"Front Pharmacol"},{"key":"4022_CR3","doi-asserted-by":"publisher","first-page":"e0229646","DOI":"10.1371\/journal.pone.0229646","volume":"15","author":"CR Ellis","year":"2020","unstructured":"Ellis CR, Racz R, Kruhlak NL, Kim MT, Zakharov AV, Southall N, et al. Evaluating kratom alkaloids using PHASE. PLoS One. 2020;15:e0229646. https:\/\/doi.org\/10.1371\/journal.pone.0229646.","journal-title":"PLoS One"},{"key":"4022_CR4","doi-asserted-by":"publisher","first-page":"e200415","DOI":"10.2903\/j.efsa.2022.e200415","volume":"20","author":"G Papadi","year":"2022","unstructured":"Papadi G, Bakhiya N, Ildico Hirsch-Ernst K. Assessment of the possible health risks associated with the consumption of botanical preparations of Mitragyna speciosa (kratom). EFSA Journal. 2022;20:e200415. https:\/\/doi.org\/10.2903\/j.efsa.2022.e200415.","journal-title":"EFSA Journal"},{"key":"4022_CR5","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.dadr.2023.100142","volume":"7","author":"JE Henningfield","year":"2023","unstructured":"Henningfield JE, Chawarski MC, Garcia-Romeu A, Grundmann O, Harun N, Hassan Z, et al. Kratom withdrawal: discussions and conclusions of a scientific expert forum. Drug Alcohol Depend Rep. 2023;7:100142. https:\/\/doi.org\/10.1016\/j.dadr.2023.100142.","journal-title":"Drug Alcohol Depend Rep"},{"key":"4022_CR6","doi-asserted-by":"publisher","first-page":"117822182210958","DOI":"10.1177\/11782218221095873","volume":"16","author":"CW Striley","year":"2022","unstructured":"Striley CW, Hoeflich CC, Viegas AT, Berkowitz LA, Matthews EG, Akin LP, et al. Health effects associated with kratom (Mitragyna speciosa) and polysubstance use: a narrative review. Subst Abuse. 2022;16:11782218221095873. https:\/\/doi.org\/10.1177\/11782218221095873.","journal-title":"Subst Abuse"},{"key":"4022_CR7","doi-asserted-by":"publisher","first-page":"108235","DOI":"10.1016\/j.drugalcdep.2020.108235","volume":"215","author":"A Behnood-Rod","year":"2020","unstructured":"Behnood-Rod A, Chellian R, Wilson R, Hiranita T, Sharma A, Leon F, et al. Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. Drug Alcohol Depend. 2020;215:108235. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108235.","journal-title":"Drug Alcohol Depend"},{"key":"4022_CR8","first-page":"145","volume":"198","author":"E Macko","year":"1972","unstructured":"Macko E, Weisbach JA, Douglas B. Some observations on the pharmacology of mitragynine. Arch Int Pharmacodyn Ther. 1972;198:145\u201361.","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"4022_CR9","first-page":"75","volume":"11","author":"S Khalil Halim","year":"2020","unstructured":"Khalil Halim S, Ahmad R, John Abdullah SA. Enforcement status of the poison act 1952 against offences related to Kratom (Mitragyna Speciosa Korth) misuse in Malaysia. UUM J Leg Stud. 2020;11:75\u201393.","journal-title":"UUM J Leg Stud"},{"key":"4022_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40122-020-00151-x","volume":"9","author":"SC Eastlack","year":"2020","unstructured":"Eastlack SC, Cornett EM, Kaye AD. Kratom\u2014pharmacology, clinical implications, and outlook: a comprehensive review. Pain Ther. 2020;9:55\u201369.","journal-title":"Pain Ther"},{"key":"4022_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.drugpo.2009.12.003","volume":"21","author":"B Vicknasingam","year":"2010","unstructured":"Vicknasingam B, Narayanan S, Beng GT, Mansor SM. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy. 2010;21:283\u20138.","journal-title":"Int J Drug Policy"},{"key":"4022_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/acs.jmedchem.9b01465","volume":"63","author":"S Obeng","year":"2020","unstructured":"Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, et al. Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids. J Med Chem. 2020;63:433\u20139.","journal-title":"J Med Chem"},{"key":"4022_CR13","doi-asserted-by":"publisher","first-page":"13510","DOI":"10.1021\/acs.jmedchem.1c00726","volume":"64","author":"F Le\u00f3n","year":"2021","unstructured":"Le\u00f3n F, Obeng S, Mottinelli M, Chen Y, King TI, Berthold EC, et al. Activity of mitragyna speciosa(\u201cKratom\u201d) alkaloids at serotonin receptors. J Med Chem. 2021;64:13510\u201323.","journal-title":"J Med Chem"},{"key":"4022_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/adb.12185","volume":"21","author":"NHM Yusoff","year":"2016","unstructured":"Yusoff NHM, Suhaimi FW, Vadivelu RK, Hassan Z, R\u00fcmler A, Rotter A, et al. Abuse potential and adverse cognitive effects of mitragynine (kratom). Addict Biol. 2016;21:98\u2013110.","journal-title":"Addict Biol"},{"key":"4022_CR15","doi-asserted-by":"publisher","first-page":"136183","DOI":"10.1016\/j.neulet.2021.136183","volume":"763","author":"MA Effendy","year":"2021","unstructured":"Effendy MA, Yunusa S, Zain ZM, Hassan Z. Real time monitoring of dopamine release evoked by mitragynine (Kratom): An insight through electrochemical sensor. Neurosci Lett. 2021;763:136183 https:\/\/doi.org\/10.1016\/j.neulet.2021.136183.","journal-title":"Neurosci Lett"},{"key":"4022_CR16","doi-asserted-by":"publisher","first-page":"114169","DOI":"10.1016\/j.bbr.2022.114169","volume":"438","author":"MA Effendy","year":"2023","unstructured":"Effendy MA, Yunusa S, Mat NH, Has ATC, M\u00fcller CP, Hassan Z. The role of AMPA and NMDA receptors in mitragynine effects on hippocampal synaptic plasticity. Behav Brain Res. 2023;438:114169. https:\/\/doi.org\/10.1016\/j.bbr.2022.114169.","journal-title":"Behav Brain Res"},{"key":"4022_CR17","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1007\/s43440-023-00541-w","volume":"75","author":"S Yunusa","year":"2023","unstructured":"Yunusa S, Hassan Z, M\u00fcller CP. Mitragynine inhibits hippocampus neuroplasticity and its molecular mechanism. Pharmacol Rep. 2023;75:1488\u2013501.","journal-title":"Pharmacol Rep"},{"key":"4022_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jep.2011.04.011","volume":"136","author":"Z Utar","year":"2011","unstructured":"Utar Z, Majid MIA, Adenan MI, Jamil MFA, Lan TM. Mitragynine inhibits the COX-2 mRNA expression and prostaglandin E 2 production induced by lipopolysaccharide in RAW264.7 macrophage cells. J Ethnopharmacol. 2011;136:75\u201382.","journal-title":"J Ethnopharmacol"},{"key":"4022_CR19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.26650\/IstanbulJPharm.2024.1424150","volume":"54","author":"A Kafo","year":"2024","unstructured":"Kafo A, Elsalami R, Hassan M. Mitragyna speciosa Korth. downregulates macrophage inflammatory responses by inhibiting TLR-4 and increasing IL-10 production. \u0130stanbul J Pharm. 2024;54:350\u20138.","journal-title":"\u0130stanbul J Pharm"},{"key":"4022_CR20","doi-asserted-by":"publisher","first-page":"117909","DOI":"10.1016\/j.indcrop.2023.117909","volume":"208","author":"S Tuntiyasawasdikul","year":"2024","unstructured":"Tuntiyasawasdikul S, Junlatat J, Tabboon P, Limpongsa E, Jaipakdee N. Mitragyna speciosa ethanolic extract: Extraction, anti-inflammatory, cytotoxicity, and transdermal delivery assessments. Ind Crops Prod. 2024;208:117909 https:\/\/doi.org\/10.1016\/j.indcrop.2023.117909.","journal-title":"Ind Crops Prod"},{"key":"4022_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lfs.2005.04.042","volume":"78","author":"K Matsumoto","year":"2005","unstructured":"Matsumoto K, Yamamoto LT, Watanabe K, Yano S, Shan J, Pang PKT, et al. Inhibitory effect of mitragynine, an analgesic alkaloid from Thai herbal medicine, on neurogenic contraction of the vas deferens. Life Sci. 2005;78:187\u201394.","journal-title":"Life Sci"},{"key":"4022_CR22","doi-asserted-by":"publisher","first-page":"114251","DOI":"10.1016\/j.bbr.2022.114251","volume":"439","author":"NH Mat","year":"2023","unstructured":"Mat NH, Bakar SNS, Murugaiyah V, Chawarski MC, Hassan Z. Analgesic effects of main indole alkaloid of kratom, mitragynine in acute pain animal model. Behav Brain Res. 2023;439:114251. https:\/\/doi.org\/10.1016\/j.bbr.2022.114251.","journal-title":"Behav Brain Res"},{"key":"4022_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jep.2013.03.078","volume":"148","author":"MFA Jamil","year":"2013","unstructured":"Jamil MFA, Subki MFM, Lan TM, Majid MIA, Adenan MI. The effect of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK-N-SH neuroblastoma cell. J Ethnopharmacol. 2013;148:135\u201343.","journal-title":"J Ethnopharmacol"},{"key":"4022_CR24","doi-asserted-by":"publisher","first-page":"708055","DOI":"10.3389\/fphar.2021.708055","volume":"12","author":"IN Iman","year":"2021","unstructured":"Iman IN, Ahmad NAZ, Mohd Yusof NA, Talib UN, Norazit A, Kumar J, et al. Mitragynine (Kratom)-induced cognitive impairments in mice resemble \u03949-THC and morphine effects: reversal by cannabinoid CB1 receptor antagonism. Front Pharmacol. 2021;12:708055. https:\/\/doi.org\/10.3389\/fphar.2021.708055.","journal-title":"Front Pharmacol"},{"key":"4022_CR25","doi-asserted-by":"publisher","first-page":"e28340","DOI":"10.1371\/journal.pone.0028340","volume":"6","author":"BS Khor","year":"2011","unstructured":"Khor BS, Amar Jamil MF, Adenan MI, Chong shu-Chien A. Mitragynine attenuates withdrawal syndrome in morphine-withdrawn zebrafish. PLoS One. 2011;6:e28340. https:\/\/doi.org\/10.1371\/journal.pone.0028340.","journal-title":"PLoS One"},{"key":"4022_CR26","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1111\/bph.16352","volume":"181","author":"S Yunusa","year":"2024","unstructured":"Yunusa S, M\u00fcller CP, Hassan Z. Mitragynine (Kratom)\u2014Withdrawal behaviour and cognitive impairments can be ameliorated by an epigenetic mechanism. Br J Pharmacol. 2024;181:2070\u201384.","journal-title":"Br J Pharmacol"},{"key":"4022_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.brainresbull.2021.04.018","volume":"172","author":"R Hassan","year":"2021","unstructured":"Hassan R, Othman N, Mansor SM, M\u00fcller CP, Hassan Z. Proteomic analysis reveals brain Rab35 as a potential biomarker of mitragynine withdrawal in rats. Brain Res Bull. 2021;172:139\u201350.","journal-title":"Brain Res Bull"},{"key":"4022_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.7150\/ijms.78861","volume":"20","author":"M Basheer","year":"2023","unstructured":"Basheer M, Hassan Z, Gam LH. Upregulation of brain\u2019s calcium binding proteins in mitragynine dependence: a potential cellular mechanism to addiction. Int J Med Sci. 2023;20:102\u201313.","journal-title":"Int J Med Sci"},{"key":"4022_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.taap.2016.05.022","volume":"305","author":"YL Tay","year":"2016","unstructured":"Tay YL, Teah YF, Chong YM, Jamil MFA, Kollert S, Adenan MI, et al. Mitragynine and its potential blocking effects on specific cardiac potassium channels. Toxicol Appl Pharmacol. 2016;305:22\u201339.","journal-title":"Toxicol Appl Pharmacol"},{"key":"4022_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.toxlet.2019.11.005","volume":"319","author":"SH Kamble","year":"2020","unstructured":"Kamble SH, Sharma A, King TI, Berthold EC, Le\u00f3n F, Meyer PKL, et al. Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids. Toxicol Lett. 2020;319:148\u201354.","journal-title":"Toxicol Lett"},{"key":"4022_CR31","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/ptr.5942","volume":"31","author":"VK Manda","year":"2017","unstructured":"Manda VK, Avula B, Dale OR, Ali Z, Khan IA, Walker LA, et al. PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids. Phytother Res. 2017;31:1935\u201345.","journal-title":"Phytother Res"},{"key":"4022_CR32","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1021\/jacs.6b00360","volume":"138","author":"AC Kruegel","year":"2016","unstructured":"Kruegel AC, Gassaway MM, Kapoor A, V\u00e1radi A, Majumdar S, Filizola M, et al. Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016;138:6754\u201364.","journal-title":"J Am Chem Soc"},{"key":"4022_CR33","doi-asserted-by":"publisher","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","volume":"59","author":"A V\u00e1radi","year":"2016","unstructured":"V\u00e1radi A, Marrone GF, Palmer TC, Narayan A, Szab\u00f3 MR, Le Rouzic V, et al. Mitragynine\/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit \u03b2-arrestin-2. J Med Chem. 2016;59:8381\u201397.","journal-title":"J Med Chem"},{"key":"4022_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.brainresbull.2016.03.015","volume":"126","author":"FW Suhaimi","year":"2016","unstructured":"Suhaimi FW, Yusoff NHM, Hassan R, Mansor SM, Navaratnam V, M\u00fcller CP, et al. Neurobiology of kratom and its main alkaloid mitragynine. Brain Res Bull. 2016;126:29\u201340.","journal-title":"Brain Res Bull"},{"key":"4022_CR35","doi-asserted-by":"publisher","unstructured":"Ramachandram DS, Damodaran T, Zainal H, Murugaiyah V, Ramanathan S Pharmacokinetics and pharmacodynamics of mitragynine, the principle alkaloid of Mitragyna speciosa: present knowledge and future directions in perspective of pain. J Basic Clin Physiol Pharmacol 2020;31. https:\/\/doi.org\/10.1515\/jbcpp-2019-0138.","DOI":"10.1515\/jbcpp-2019-0138"},{"key":"4022_CR36","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/molecules29050984","volume":"29","author":"MA Huestis","year":"2024","unstructured":"Huestis MA, Brett MA, Bothmer J, Atallah R. Human mitragynine and 7-hydroxymitragynine pharmacokinetics after single and multiple daily doses of oral encapsulated dried kratom leaf powder. Molecules. 2024;29:984 https:\/\/doi.org\/10.3390\/molecules29050984.","journal-title":"Molecules"},{"key":"4022_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12917-020-02451-y","volume":"16","author":"N Percie Du Sert","year":"2020","unstructured":"Percie Du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMC Vet Res. 2020;16:242 https:\/\/doi.org\/10.1186\/s12917-020-02451-y.","journal-title":"BMC Vet Res"},{"key":"4022_CR38","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s00213-015-3866-5","volume":"232","author":"N Harun","year":"2015","unstructured":"Harun N, Hassan Z, Navaratnam V, Mansor SM, Shoaib M. Discriminative stimulus properties of mitragynine (kratom) in rats. Psychopharmacology (Berl). 2015;232:2227\u201338.","journal-title":"Psychopharmacology (Berl)"},{"key":"4022_CR39","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/adb.12639","volume":"24","author":"SE Hemby","year":"2019","unstructured":"Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol. 2019;24:874\u201385.","journal-title":"Addict Biol"},{"key":"4022_CR40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1124\/jpet.120.000189","volume":"376","author":"S Obeng","year":"2021","unstructured":"Obeng S, Wilkerson JL, Le\u00f3n F, Reeves ME, Restrepo LF, Gamez-Jimenez LR, et al. Pharmacological comparison of mitragynine and 7-hydroxymitragynine: in vitro affinity and efficacy for \u03bc-opioid receptor and opioid-like behavioral effects in rats. J Pharmacol Exp Ther. 2021;376:410\u201327.","journal-title":"J Pharmacol Exp Ther"},{"key":"4022_CR41","first-page":"238","volume":"7","author":"AM Rusydan","year":"2022","unstructured":"Rusydan AM, Lukitaningsih E, Fakhrudin N. Mitragyna speciosa: opioid addiction treatment and risk of use. JPSCR: J Pharm Sci Clin Res. 2022;7:238.","journal-title":"JPSCR: J Pharm Sci Clin Res"},{"key":"4022_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.alcohol.2021.11.003","volume":"98","author":"O Yunuso\u011flu","year":"2022","unstructured":"Yunuso\u011flu O. Rewarding effect of ethanol-induced conditioned place preference in mice: effect of the monoterpenoid linalool. Alcohol. 2022;98:55\u201363.","journal-title":"Alcohol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04022-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04022-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04022-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T02:40:51Z","timestamp":1779849651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04022-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4022"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04022-5","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}